#

Biotechnology

: 100
Once the deal closes, Esperion will be delisted from the Nasdaq, which removes a once-public cardiometabolic pure-play from the small-cap biotech universe, notes Noble / Photo: Instagram / Esperioninc
Small Caps·
Small-cap biotech Esperion to be taken private by ARCHIMED; shares jump more than 50%
Small caps last week: Peloton on Spotify, biotech M&A, small-cap ETF leaders
Small Caps·
Small caps last week: Peloton on Spotify, biotech M&A, small-cap ETF leaders
Hemab is developing therapies for blood coagulation disorders such as Glanzmann thrombasthenia and Von Willebrand Disease, according to its filings / Photo: Hemab Therapeutics
Small Caps·
+1
·
Hemab IPO: Novo-backed blood disorder biotech debuts on the Nasdaq
Seaport Therapeutics shares become available / Photo: Seaport Therapeutics
News·
IPO of Seaport Therapeutics: shares of the antidepressant developer become available
KalVista shares soared after a deal with the private Italian pharma company Chiesi / Photo: KalVista
Small Caps·
Small-cap biotech KalVista to be acquired by Italy's Chiesi; stock hits 5-year high
Boston-based biotech Avalyn Pharma develops inhaled drugs / Photo: Avalyn Pharma
News·
Avalyn Pharma IPO: Novo Nordisk-backed biotech goes public
Freedom Broker has looked at which small caps in the biotech space were most popular among hedge funds in the fourth quarter / Photo: Shutterstock.com
Small Caps·
Up to 840% upside: 10 smid-cap biotechs most popular with hedge funds
Revolution Medicines in April announced unprecedented results for its pancreatic cancer drug. Its shares have risen nearly 300% in a year. Photo: LinkedIn page
Review·
How oncology company Revolution Medicines monetized a year of operations in 48 hours
Eli Lilly to buy cancer drug developer Kelonia / Photo: Jonathan Weiss / Shutterstock.com
News·
Eli Lilly to buy oncology drug developer. What is it paying up to $7 billion for?
Kailera Therapeutics Inc. has raised $625 million in an upsized IPO, marking the sector’s biggest U.S. listing since 2021 / Photo: Kailera
News·
+1
·
Kailera Therapeutics IPO: Shares of obesity drugmaker start trading
Biotech Alamar Biosciences is listed on the Nasdaq under the ticker ALMR / Photo: Dr. Ying / Shutterstock
News·
Alamar IPO: shares of the biotech, whose mission is the early diagnosis of diseases, became available
Soleno Therapeutics shares jumped after the company won U.S. approval for its drug to treat hyperphagia, a condition caused by a genetic disorder / Photo: Unsplash / Photosomething
Small Caps·
Extreme hunger drugmaker Soleno jumps on potential acquisition by Neurocrine
Load more